A Randomized, Double Blind, Placebo-controlled, 3-arm, Parallel-group, 26-week, Multicenter Study With A 26-week Extension To Evaluate The Efficacy, Safety And Tolerability Of Canagliflozin In The Treatment Of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment